Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Conditions:   Breast Cancer;   Ovarian Cancer;   Liposarcoma;   Non-small Cell Lung Cancer (NSCLC);   Endometrial;   Solid Tumors Interventions:   Drug: PF-07224826;   Combination Product: Fulvestrant Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials